My calculations for Q3FY19 have Lifx revenue as A$8.219m (71% growth).Q3FY19: Total Revenue A$8.750m = BUD A$0.531m, LIFX A$8.219mQ3FY18: Total Revenue A$5.302m = BUD A$0.505m, LIFX A$4.797m
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%